How many clinical trials are tracked of ublituximab?

6 trials are tracked, 3 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Nephrology Emergency Medicine Physical Medicine & Rehab Urology Hematology Ophthalmology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

ublituximab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of ublituximab

6 trials tracked of ublituximab: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 209 citations.

6Trials tracked

3Phase 3 & 4

0Recruiting

3With published results

Phase distribution

Phase 3 3 Phase 2 2 Phase 1 1

Phase 3 Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) Completed · 209 cited
Phase 3 Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) Completed · 208 cited
Phase 3 Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) Completed · 50 cited
Phase 2 Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma Completed
Phase 2 Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis Completed
Phase 1 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.